Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats

Transplantation

Volumn 95, Issue 2, 2013, Pages 280-284

  Shivaswamy, Vijay ^a,b   Bennett, Robert G ^a   Clure, Cara C ^a   Larsen, Jennifer L ^a   Hamel, Frederick G ^a  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Diabetes; Immunosuppression; Metformin.; Transplant

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; RAPAMYCIN; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; EXOCRINE GLAND MALFORMATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; NICK END LABELING; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DISEASE MODELS, ANIMAL; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; IN SITU NICK-END LABELING; INSULIN; MALE; METFORMIN; PANCREAS, EXOCRINE; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TACROLIMUS; TIME FACTORS;

EID: 84872914827     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318275a322     Document Type: Article

References (34)

1. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75: SS3.
2. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of earlydiagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588.
3. Sulanc E, Lane JT, Puumala SE, et al. New-onset diabetes after kidney transplantation: an application of 2003 international guidelines. Transplantation 2005; 80: 945.
4. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
5. Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59: 732.
6. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
7. Porrini E, Moreno JM, Osuna A, et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. Transplantation 2008; 85: 1133.
8. Sui W, Zou H, Zou G, et al. Clinical study of the risk factors of insulin resistance and metabolic syndrome after kidney transplantation. Transpl Immunol 2008; 20: 95.
9. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590.
10. Crutchlow MF, Bloom RD. Transplant-associated hyperglycemia: a new look at an old problem. Clin J Am Soc Nephrol 2007; 2: 343.
11. Hjelmesaeth J, Jenssen T, Hagen M, et al. Determinants of insulin secretion after renal transplantation. Metabolism 2003; 52: 573.
12. Oetjen E, Baun D, Beimesche S, et al. Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol 2003; 63: 1289.
13. Radu RG, Fujimoto S, Mukai E, et al. Tacrolimus suppresses glucoseinduced insulin release from pancreatic islets by reducing glucokinase activity. Am J Physiol Endocrinol Metab 2005; 288: E365.
14. Redmon JB, Olson LK, Armstrong MB, et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996; 98: 2786.
15. Johnson JD, Ao Z, Ao P, et al. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant 2009; 18: 833.
16. Chien YS, Chen YT, Chuang CH, et al. Incidence and risk factors of new-onset diabetes mellitus after renal transplantation. Transplant Proc 2008; 40: 2409.
17. Veroux M, Corona D, Giuffrida G, et al. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transplant Proc 2008; 40: 1885.
18. Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411.
19. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52: 2731.
20. Bussiere CT, Lakey JR, Shapiro AM, et al. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006; 49: 2341.
21. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008; 57: 945.
22. Hakeam HA, Al-Jedai AH, Raza SM, et al. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. Ann Transplant 2008; 13: 46.
23. Zahr E, Molano RD, Pileggi A, et al. Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation 2007; 84: 1576.
24. Larsen JL, Bennett RG, Burkman T, et al. Tacrolimus and sirolimus cause insulin resistance in normal Sprague Dawley rats. Transplantation 2006; 82: 466.
25. Ratner RE. An update on the Diabetes Prevention Program. Endocr Pract 2006; 12: 20.
26. Sharif A. Should metformin be our antiglycemic agent of choice posttransplantation? Am J Transplant 2011; 11: 1376.
27. Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract 2008; 14: 979.
28. Bonner-Weir S, Baxter LA, Schuppin GT, et al. A second pathway for regeneration of adult exocrine and endocrine pancreas. A possible recapitulation of embryonic development. Diabetes 1993; 42: 1715.
29. Bonner-Weir S. Perspective: postnatal pancreatic beta cell growth. Endocrinology 2000; 141: 1926.
30. Bouwens L, Rooman I. Regulation of pancreatic beta-cell mass. Physiol Rev 2005; 85: 1255.
31. Yalow RS. Radioimmunoassay: a probe for the fine structure of biologic systems. Science 1978; 200: 1236.
32. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960; 39: 1157.
33. Volosov A, Napoli KL, Soldin SJ. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatographyYtandem mass-spectrometry. Clin Biochem 2001; 34: 285.
34. Abramoff MD, Magalhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int 2004; 11: 36.